News | May 02, 2014

Analogic Enters Agreement to Distribute Prostate Guidance Solution

Analogic to offer D&K's BioJet Fusion system with Flex Focus ultrasound for precise, targeted prostate biopsies

Analogic Corp. BK Flex Focus D&K Technologies BioJet Solution Prostate Biopsy

May 2, 2014 — Analogic Corp. has entered into a distribution agreement with D&K Technologies, developer of the BioJet Solution, a revolutionary 3-D magnetic resonance imagining (MRI) transrectal ultrasound (TRUS) fusion technology. Analogic will distribute the BioJet system for use with its BK Flex Focus ultrasound systems, for assistance during precise, targeted prostate biopsies, in Austria, Belgium, Denmark, Germany, Great Britain, Luxemburg, North America, Sweden Switzerland and The Netherlands.

The BioJet Fusion system overlays real-time ultrasound images from the BK Flex Focus ultrasound system with MRI identified lesions to provide real-time guidance during prostate biopsies. Analogic's European launch of this advanced technology for MRI/ultrasound fusion guided biopsies took place at the 29th Annual European Association of Urology (EAU) Congress in Stockholm, Sweden, April 11-15.

The combination of the Flex Focus and BioJet offers a complete system that will support both transperineal and transrectal biopsy methods. The BK endocavity biplane transducer (8848) is ideal for transperineal fusion biopsies. In addition, there are two options for transrectal fusion biopsies — the BK triplane (8818) and BK biplane transducer (8808e). Data is easily imported and exported allowing for a more convenient working process between urologists and radiologists.

Comprehensive biopsy reports contain fused MRI and ultrasound images, and biopsy cores. The complete system is simple to use with an intuitive user interface that includes easy contouring and fine-tuning, designed specifically for busy urology practices. Finally, the Flex Focus with the BioJet system has a small footprint, enabling it to fit into tight spaces in a clinic or practice.

For more information: www.analogicultrasound.com/fusion

Related Content

Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Immune Response Prognostic for Prostate Cancer Survival, Recurrence and Radiotherapy Response
News | Prostate Cancer | October 03, 2017
A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017
Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC) covering North Carolina,...
Overlay Init